SCHEMBL4849232

SCHEMBL4849232

O=C(NCCO)c1ccc(CC23CCCN2C(=O)N(c2cc(Cl)cc(Cl)c2)C3=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 3/20 0.40
MAPT P10636 2/20 0.38
CHRNA7 P36544 1/20 0.38
MCHR1 Q99705 5/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
CYP2D6 P10635 1/20 0.37
CHRM1 P11229 1/20 0.37
HTR2A P28223 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HTR1A P08908 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
KCNH2 Q12809 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
ITGB2 P05107 1/20 0.35
ICAM1 P05362 1/20 0.35
ITGAL P20701 1/20 0.35
GLP1R P43220 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4847326 0.85 ITGAL (0.39) MAPTPOLBALDH1A1ITGB2ICAM1
SCHEMBL4847479 0.82 ITGAL (0.39) MCHR1HTR1AKCNH2ITGB2ICAM1
SCHEMBL4849224 0.81 ITGAL (0.38) ITGB2ICAM1ITGAL
SCHEMBL4849069 0.81 LMNA (0.44) MAPTPOLBHPGDHTTALDH1A1
SCHEMBL4841707 0.80 ITGAL (0.55) ITGB2ICAM1ITGAL
SCHEMBL14254855 0.79 ITGAL (0.46) POLBKCNH2ITGB2ICAM1ITGAL
SCHEMBL4846983 0.77 ITGAL (0.42) ITGB2ICAM1ITGALMETAP2MAPK8
SCHEMBL4845276 0.77 ITGAL (0.42) ITGB2ICAM1ITGALMETAP2
SCHEMBL4847498 0.77 ITGAL (0.39) ALDH1A1KCNH2ITGB2ICAM1ITGAL
SCHEMBL4840686 0.77 ITGAL (0.54) ITGB2ICAM1ITGAL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342012-B2 Inhibitors of αLβ2 mediated cell adhesion MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-11 US disclosed
US-20050148602-A1 Inhibitors of alphaLbeta2 mediated cell adhesion TANABE SEIYAKU CO., LTD. 2005-07-07 US disclosed
US-6897225-B1 Inhibitors of αLβ2 mediated cell adhesion TANABE SEIYAKU CO., LTD. (JP) 2005-05-24 US disclosed
EP-1307455-B1 INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION TANABE SEIYAKU CO (JP) 2005-04-06 EP disclosed
EP-1307455-A2 INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 2003-05-07 EP disclosed
WO-2001030781-A2 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 2001-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148602-A1 Inhibitors of alphaLbeta2 mediated cell adhesion ITGB2, ITGA2B, ITGB1 GCGR 3730/4885MAPT 2995/4885CHRNA7 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.